AACR Cancer Progress Report 2013

### AACR Staff ![Figure][1] On April 8, 2013, in an unprecedented effort to highlight the critical importance of biomedical research, the American Association for Cancer Research (AACR) joined with more than 200 organizations representing a broad spectrum of research interests and diseases

[1]  Wellmann Kf.  SMOKING AND HEALTH. ON THE REPORT OF THE ADVISORY COMMITTEE TO THE SURGEON GENERAL OF THE PUBLIC HEALTH SERVICE , 1964 .

[2]  H. Earl,et al.  aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  W. Demark-Wahnefried,et al.  Obesity, Energy Balance, and Cancer: New Opportunities for Prevention , 2012, Cancer Prevention Research.

[4]  Michael J Thun,et al.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.

[5]  L. Sequist,et al.  Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC). , 2013 .

[6]  N. Boyd,et al.  Mammographic density and the risk and detection of breast cancer. , 2007, The New England journal of medicine.

[7]  E. Hawk,et al.  Chemoprevention--history and general principles. , 2011, Best practice & research. Clinical gastroenterology.

[8]  Office on Smoking.  How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General , 2010 .

[9]  R. Yelensky,et al.  Use of the FoundationOne next-generation sequencing (NGS) assay to detect actionable alterations leading to clinical benefit of targeted therapies for relapsed and refractory breast cancer. , 2013 .

[10]  Yin Cao,et al.  Body Mass Index, Prostate Cancer–Specific Mortality, and Biochemical Recurrence: a Systematic Review and Meta-analysis , 2011, Cancer Prevention Research.

[11]  Luke A. Stewart,et al.  Leadership in Decline: Assessing U.S. International Competitiveness in Biomedical Research , 2012 .

[12]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[13]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[14]  D. Aberle,et al.  Results of initial low-dose computed tomographic screening for lung cancer. , 2013, The New England journal of medicine.

[15]  C. Klein,et al.  Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. , 2010, Blood.

[16]  D. Lowy,et al.  Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica , 2013, PloS one.

[17]  Michael J Thun,et al.  American Journal of Epidemiology Original Contribution Leisure Time Spent Sitting in Relation to Total Mortality in a Prospective Cohort of Us Adults , 2022 .

[18]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[19]  M. Falster,et al.  Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis , 2007, The Lancet.

[20]  C. Ulrich,et al.  Exercise, Energy Balance and Cancer , 2013 .

[21]  A. Arai,et al.  Submillisievert median radiation dose for coronary angiography with a second-generation 320-detector row CT scanner in 107 consecutive patients. , 2013, Radiology.

[22]  S. Gapstur,et al.  Associations of recreational physical activity and leisure time spent sitting with colorectal cancer survival. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Gail M Williams,et al.  Reduced melanoma after regular sunscreen use: randomized trial follow-up. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Yoshiyuki Watanabe,et al.  Prospective cohort study of the risk of prostate cancer among rotating-shift workers: findings from the Japan collaborative cohort study. , 2006, American journal of epidemiology.

[25]  David Satcher,et al.  Women and smoking: a report of the Surgeon General. , 2002, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[26]  C. Rock,et al.  Nutrition and physical activity guidelines for cancer survivors , 2012, CA: a cancer journal for clinicians.

[27]  F. Bull,et al.  Long-term sedentary work and the risk of subsite-specific colorectal cancer. , 2011, American journal of epidemiology.

[28]  Judith A. Smith,et al.  Clinical Perspectives on the Role of the Human Papillomavirus Vaccine in the Prevention of Cancer , 2011, Pharmacotherapy.

[29]  J. Meyerhardt,et al.  Impact of Diabetes on Oncologic Outcome of Colorectal Cancer Patients: Colon vs. Rectal Cancer , 2013, PloS one.

[30]  Qing He,et al.  CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.

[31]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[32]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[33]  M. Weinstock,et al.  Indoor Tanning and Risk of Melanoma: A Case-Control Study in a Highly Exposed Population , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[34]  D. Hunter,et al.  Use of tanning beds and incidence of skin cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  I. Flinn,et al.  Ponatinib in refractory Philadelphia chromosome-positive leukemias. , 2012, The New England journal of medicine.

[36]  D. Sargent,et al.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[37]  M. Socinski,et al.  Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  S. Marx,et al.  Bench to bedside: the development of rapamycin and its application to stent restenosis. , 2001, Circulation.

[39]  Manuel Hidalgo,et al.  Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer , 2010, Molecular Cancer Therapeutics.

[40]  M. Hallek,et al.  Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial. , 2013 .

[41]  A. Bleyer,et al.  Effect of three decades of screening mammography on breast-cancer incidence. , 2012, The New England journal of medicine.

[42]  K. Straif,et al.  A review of human carcinogens--Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. , 2009, The Lancet. Oncology.

[43]  M. Dimopoulos,et al.  Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma , 2013, OncoTargets and therapy.

[44]  E. Paskett,et al.  Eliminating racial disparities in colorectal cancer in the real world: it took a village. , 2013, Delaware medical journal.

[45]  Donghui Li.  Diabetes and pancreatic cancer , 2012, Molecular carcinogenesis.

[46]  K. Straif,et al.  A review of human carcinogens--Part B: biological agents. , 2009, The Lancet. Oncology.

[47]  N. Berger.  Cancer and Energy Balance, Epidemiology and Overview , 2010 .

[48]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[49]  J. Forbes,et al.  A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. , 2005, The New England journal of medicine.

[50]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[51]  Linda K. Han,et al.  Comparative Evaluation of [99mTc]Tilmanocept for Sentinel Lymph Node Mapping in Breast Cancer Patients: Results of Two Phase 3 Trials , 2013, Annals of Surgical Oncology.

[52]  S. Ogino,et al.  Aspirin Use and Survival After Diagnosis of Colorectal Cancer , 2009 .

[53]  F Laden,et al.  Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. , 2001, Journal of the National Cancer Institute.

[54]  M. Forman,et al.  Energy Balance and Cancer , 2006 .

[55]  P. Moore,et al.  Merkel cell carcinoma: a virus-induced human cancer. , 2012, Annual review of pathology.

[56]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[57]  M. Gould,et al.  When the Average Applies to No One: Personalized Decision Making About Potential Benefits of Lung Cancer Screening , 2012, Annals of Internal Medicine.

[58]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[59]  Martin Krapcho,et al.  SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations) , 2012 .

[60]  A. Sancar,et al.  Circadian regulation of DNA excision repair: Implications for chrono-chemotherapy , 2009, Cell cycle.

[61]  G. Maskarinec,et al.  The effect of migration on cancer incidence among Japanese in Hawaii. , 2004, Ethnicity & disease.

[62]  Jenny Jeyarajah,et al.  Human Papillomavirus Vaccination Coverage Among Adolescents, 2007–2013, and Postlicensure Vaccine Safety Monitoring, 2006–2014 — United States , 2014, MMWR. Morbidity and mortality weekly report.

[63]  Sheila Weinmann,et al.  The use of computed tomography in pediatrics and the associated radiation exposure and estimated cancer risk. , 2013, JAMA pediatrics.

[64]  M. Pishvaian,et al.  Current management of inflammatory bowel disease and colorectal cancer. , 2011, Gastrointestinal cancer research : GCR.

[65]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[66]  H. El‐Serag,et al.  Sleep duration and incidence of colorectal cancer in postmenopausal women , 2013, British Journal of Cancer.

[67]  S. Hankinson,et al.  Night shift work and the risk of endometrial cancer. , 2007, Cancer research.

[68]  Reiko Nishihara,et al.  Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. , 2012, The New England journal of medicine.

[69]  Sung-Bae Kim,et al.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.

[70]  J. Wolchok,et al.  Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[71]  J. Blay,et al.  Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[72]  N. Aziz.  Cancer Survivorship Research , 2020, Definitions.

[73]  A. Creanga,et al.  Abortion surveillance--United States, 2009. , 2012, Morbidity and mortality weekly report. Surveillance summaries.

[74]  C. Gross,et al.  Racial disparities in cancer therapy , 2008, Cancer.

[75]  Kurt Straif,et al.  A review of human carcinogens--part D: radiation. , 2009, The Lancet. Oncology.

[76]  J. Wactawski‐Wende,et al.  Sleep disturbance and incidence of thyroid cancer in postmenopausal women the Women's Health Initiative. , 2013, American journal of epidemiology.

[77]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[78]  M. Roobol,et al.  Risk stratification in prostate cancer screening , 2013, Nature Reviews Urology.

[79]  Francine Laden,et al.  Night-shift work and risk of colorectal cancer in the nurses' health study. , 2003, Journal of the National Cancer Institute.

[80]  David M. Thomas,et al.  Giant cell tumour of bone , 2009, Current opinion in oncology.

[81]  E. Gale,et al.  The influence of glucose-lowering therapies on cancer risk in type 2 diabetes , 2009, Diabetologia.

[82]  E. Jaffee,et al.  Interim safety and efficacy analysis of a phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer. , 2013 .

[83]  C. Bollard.  Improving T-cell therapy for epstein-barr virus lymphoproliferative disorders. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  Eric J Feuer,et al.  Projections of the cost of cancer care in the United States: 2010-2020. , 2011, Journal of the National Cancer Institute.

[85]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[86]  J. Marshall,et al.  A Randomized Phase II Study of Immunization With Dendritic Cells Modified With Poxvectors Encoding CEA and MUC1 Compared With the Same Poxvectors Plus GM-CSF for Resected Metastatic Colorectal Cancer , 2013, Annals of surgery.

[87]  Mark Schiffman,et al.  Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. , 2011, The Lancet. Oncology.

[88]  Prabhat Jha,et al.  21st-century hazards of smoking and benefits of cessation in the United States. , 2013, The New England journal of medicine.

[89]  Michael J Thun,et al.  50-year trends in smoking-related mortality in the United States. , 2013, The New England journal of medicine.

[90]  Edward Giovannucci,et al.  Diabetes and Cancer , 2010, Diabetes Care.

[91]  E. Unger,et al.  Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. , 2013, The Journal of infectious diseases.

[92]  Mohammad Hassan Murad,et al.  Early detection of prostate cancer: AUA Guideline. , 2013, The Journal of urology.

[93]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[94]  Dirk Schadendorf,et al.  Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .

[95]  W. Wilson,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.

[96]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[97]  Peter Boyle,et al.  Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis , 2012, BMJ : British Medical Journal.

[98]  D. Clarke‐Pearson,et al.  Screening for Ovarian Cancer , 2009 .

[99]  Division on Earth.  Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2 , 2006 .

[100]  D. Brenner,et al.  Computed tomography--an increasing source of radiation exposure. , 2007, The New England journal of medicine.

[101]  David M. Thomas,et al.  Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone , 2012, Clinical Cancer Research.

[102]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[103]  M. Antoch,et al.  Circadian proteins in the regulation of cell cycle and genotoxic stress responses. , 2007, Trends in cell biology.

[104]  Scott D Ramsey,et al.  A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program. , 2010, Journal of the National Cancer Institute.

[105]  Lisa M. Schwartz,et al.  Cancer screening campaigns--getting past uninformative persuasion. , 2012, The New England journal of medicine.

[106]  Ahmedin Jemal,et al.  Annual Report to the Nation on the status of cancer, 1975‐2008, featuring cancers associated with excess weight and lack of sufficient physical activity , 2012, Cancer.

[107]  Mary C. White,et al.  Cancer screening - United States, 2010. , 2012, MMWR. Morbidity and mortality weekly report.

[108]  J. Kirkwood,et al.  Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[110]  J. A. Alvarez.  N of 1. , 2003, Journal of neurosurgery.

[111]  D. Blask,et al.  Melatonin, sleep disturbance and cancer risk. , 2009, Sleep medicine reviews.

[112]  N. Crum‐Cianflone,et al.  Sleep Characteristics, Mental Health, and Diabetes Risk , 2013, Diabetes Care.

[113]  F. Hobbs,et al.  Age and Sex Composition , 2004 .

[114]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[115]  N. Day,et al.  TRENDS IN MORTALITY FROM CERVICAL CANCER IN THE NORDIC COUNTRIES: ASSOCIATION WITH ORGANISED SCREENING PROGRAMMES , 1987, The Lancet.

[116]  Sameer M. Siddiqi,et al.  Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. , 2012, Journal of the National Cancer Institute.

[117]  Brendan J. Quinn,et al.  Repositioning metformin for cancer prevention and treatment , 2013, Trends in Endocrinology & Metabolism.

[118]  S. Habib,et al.  Diabetes and Risk of Cancer , 2013, ISRN oncology.

[119]  J. Taube,et al.  Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody , 2012, Clinical Cancer Research.

[120]  T. Robak,et al.  New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies , 2011, BioDrugs.

[121]  D. Pardoll.  Immunology beats cancer: a blueprint for successful translation , 2012, Nature Immunology.

[122]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[123]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[124]  M. Hidalgo,et al.  Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates. , 2013 .

[125]  G. Colditz,et al.  Preventability of cancer: the relative contributions of biologic and social and physical environmental determinants of cancer mortality. , 2012, Annual review of public health.

[126]  P. Kantoff,et al.  Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  Benjamin D Smith,et al.  Future of cancer incidence in the United States: burdens upon an aging, changing nation. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[128]  C. Sander,et al.  Genome Sequencing Identifies a Basis for Everolimus Sensitivity , 2012, Science.

[129]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[130]  V. Sondak,et al.  Combined Analysis of Phase III Trials Evaluating [99mTc]Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneous Melanoma , 2012, Annals of Surgical Oncology.

[131]  Katherine M Flegal,et al.  Prevalence of obesity in the United States, 2009-2010. , 2012, NCHS data brief.

[132]  R. Gelber,et al.  Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. , 2011, The Lancet. Oncology.

[133]  G. Salles,et al.  Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. , 2012, Blood.

[134]  A. Sancar,et al.  Circadian oscillation of nucleotide excision repair in mammalian brain , 2009, Proceedings of the National Academy of Sciences.

[135]  R Peto,et al.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[136]  Ming-Feng Hou,et al.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial , 2013, The Lancet.

[137]  C. Redfern,et al.  A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC). , 2013 .

[138]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[139]  E. Ziv,et al.  European Ancestry Is Positively Associated with Breast Cancer Risk in Mexican Women , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[140]  Connie Lim,et al.  Youth risk behavior surveillance - United States, 2011. , 2012, Morbidity and mortality weekly report. Surveillance summaries.

[141]  H. Kantarjian,et al.  Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. , 2012, Blood.

[142]  Li Ding,et al.  Activating HER2 mutations in HER2 gene amplification negative breast cancer. , 2013, Cancer discovery.

[143]  E. Riboli,et al.  The second expert report, Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective , 2007 .

[144]  H. Scher,et al.  Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[145]  Susan Halabi,et al.  A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. , 2003, The New England journal of medicine.

[146]  M Baum,et al.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.

[147]  A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer , 2011, Molecular Cancer Therapeutics.

[148]  A. Jemal,et al.  Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. , 2012, The Lancet. Oncology.

[149]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[150]  K. Courneya,et al.  American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. , 2010, Medicine and science in sports and exercise.

[151]  Terry Young,et al.  Sleep-disordered breathing and cancer mortality: results from the Wisconsin Sleep Cohort Study. , 2012, American journal of respiratory and critical care medicine.

[152]  Graham A Colditz,et al.  Physical activity and survival after colorectal cancer diagnosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[153]  M. Irwin.  Benefits of Aerobic and Resistance Exercise for Cancer Survivors , 2013 .

[154]  G. Salles,et al.  Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia. , 2009 .

[155]  M. Plummer,et al.  Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. , 2012, The Lancet. Oncology.

[156]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[157]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[158]  P. L. Bergsagel,et al.  Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[159]  V. Giuliano,et al.  Improved breast cancer detection in asymptomatic women using 3D-automated breast ultrasound in mammographically dense breasts. , 2013, Clinical imaging.

[160]  B. Monk,et al.  Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.